<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875952</url>
  </required_header>
  <id_info>
    <org_study_id>Informed Consent:552 / 306</org_study_id>
    <secondary_id>000000000014520</secondary_id>
    <nct_id>NCT01875952</nct_id>
  </id_info>
  <brief_title>Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)</brief_title>
  <acronym>HIV/TB</acronym>
  <official_title>Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Salud Publica, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Salud Publica, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine of once identified to the subjects infected with
      human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat
      her with isoniazid for six months, measuring the production of Interferon range pre and
      posttreatment, to evaluate this way the result of the treatment on the immune response
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A descriptive analysis of the data will be made. Means and standard deviations for continuous
      data frequencies for categorical data will be performed. Wilcoxon test Mann-Whitney U test
      Chi square will be used for frequency analysis of responders Data Analysis and Statistical
      Software(STATA).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Production of interferon gamma, in response to treatment of latent infection</measure>
    <time_frame>Before and after treatment intake</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <condition>Tuberculosis (TB)</condition>
  <condition>Latent Tuberculosis Infection (LTI)</condition>
  <arm_group>
    <arm_group_label>one arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients with response to positive purified protein derivative (PPD) test are treated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months</description>
    <arm_group_label>one arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Accept to participate. Informed consent.

          -  Human Immunodeficiency Virus positive test, documented by Western Blot

          -  Have not received treatment for latent tuberculosis

          -  Have not been diagnosed pulmonary tuberculosis (Tbp)

          -  Normal two chest X-rays, Postern-anterior and left lateral.

        Exclusion Criteria:

          -  Active tuberculosis

          -  Previous diagnosis of tuberculosis

          -  Antecedent of treatment for active o latent tuberculosis

          -  Contact with TB patient harboring Multidrug resistance or isoniazid resistant isolates
             of Mycobacterium tuberculosis.

          -  Abnormal liver enzyme levels

          -  Hemoglobin below 8 gr/dl

          -  Allergy or intolerance to isoniazid

          -  Peripheral neuropathy

          -  Ingestion of drugs interacting with isoniazid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Sifuentes, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nitrición Salvador Zubiran (INCMNSZ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Ponce-de-León, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutrición (INCMNSZ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria de Lourdes García-García, Post doctor</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Nacional de Salud Publica (INSP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Luis Valdespino-Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratorios Nacionales de Biológicos y Reactrivos (BIRMEX)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Torres Rojas, Post Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases (INER)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Salud Publica</name>
      <address>
        <city>Mexico</city>
        <state>Cuernavaca Morelos</state>
        <zip>62100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Especializada CONDESA</name>
      <address>
        <city>Mexico City</city>
        <state>D.F</state>
        <zip>06140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Salud Publica, Mexico</investigator_affiliation>
    <investigator_full_name>Ma. de Lourdes Garcia Garcia</investigator_full_name>
    <investigator_title>Director of the Center of Research in Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Latent tuberculosis infection</keyword>
  <keyword>Human immunodeficiency virus (HIV)</keyword>
  <keyword>Treatment</keyword>
  <keyword>Isoniazid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

